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Summary
BACKGROUND: As clinical signs of COVID-19 differ
widely among individuals, from mild to severe, the defin-
ition of risk groups has important consequences for rec-
ommendations to the public, control measures and patient
management, and needs to be reviewed regularly.
AIM: The aim of this study was to explore risk factors for
in-hospital mortality and intensive care unit (ICU) admis-
sion for hospitalised COVID-19 patients during the first
epidemic wave in Switzerland, as an example of a country
that coped well during the first wave of the pandemic.
METHODS: This study included all (n = 3590) adult poly-
merase chain reaction (PCR)-confirmed hospitalised pa-
tients in 17 hospitals from the hospital-based surveillance
of COVID-19 (CH-Sur) by 1 September 2020. We calcu-
lated univariable and multivariable (adjusted) (1) propor-
tional hazards (Fine and Gray) survival regression models
and (2) logistic regression models for in-hospital mortality
and admission to ICU, to evaluate the most common co-
morbidities as potential risk factors.
RESULTS AND DISCUSSION: We found that old age
was the strongest factor for in-hospital mortality after hav-
ing adjusted for gender and the considered comorbidities
(hazard ratio [HR] 2.46, 95% confidence interval [CI]
2.33−2.59 and HR 5.6 95% CI 5.23−6 for ages 65 and 80
years, respectively). In addition, male gender remained an
important risk factor in the multivariable models (HR 1.47,
95% CI 1.41−1.53). Of all comorbidities, renal disease,
oncological pathologies, chronic respiratory disease, car-
diovascular disease (but not hypertension) and dementia
were also risk factors for in-hospital mortality. With respect
to ICU admission risk, the pattern was different, as pa-
tients with higher chances of survival might have been ad-
mitted more often to ICU. Male gender (OR 1.91, 95% CI
1.58−2.31), hypertension (OR 1.3, 95% CI 1.07−1.59) and
age 55–79 years (OR 1.15, 95% CI 1.06−1.26) are risk
factors for ICU admission. Patients aged 80+ years, as
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well as patients with dementia or with liver disease were
admitted less often to ICU.
CONCLUSION: We conclude that increasing age is the
most important risk factor for in-hospital mortality of hospi-
talised COVID-19 patients in Switzerland, along with male
gender and followed by the presence of comorbidities
such as renal diseases, chronic respiratory or cardiovas-
cular disease, oncological malignancies and dementia.
Male gender, hypertension and age between 55 and 79
years are, however, risk factors for ICU admission. Mor-
tality and ICU admission need to be considered as sepa-
rate outcomes when investigating risk factors for pandem-
ic control measures and for hospital resources planning.
Introduction
As clinical signs of COVID-19 differ widely among indi-
viduals, from asymptomatic or very mild infection to se-
vere disease with often fatal outcome [1], the definition of
risk groups has important consequences for the recommen-
dations to the public, control measures such us vaccination
plans and patient management, and needs to be reviewed
regularly. Different risk groups have been reported for dif-
ferent outcomes of interest, namely hospital admission,
admission to an intensive care unit (ICU) and mortality
(which in turn can be in-hospital mortality or death without
hospitalisation). A large review of 22 published survival
models [2] concluded that “oxygen saturation on room air
and patient age are strong predictors of deterioration and
mortality among hospitalised adults with COVID-19, re-
spectively”, and that additional factors did not add value to
these univariable predictors. Extensive studies carried out
in the UK on in-hospital mortality [3] and COVID-19-re-
lated death [4] have shown that other comorbidities are al-
so associated with severe COVID-19 disease and death,
but the fully adjusted hazard ratios obtained are often un-
der 2 (except age older than 60 years, severe and acute
forms of haematological malignancy, reduced kidney func-
tion, stroke or dementia, neurological disease, organ trans-
plant and immunosuppression) [4]. Even though hyperten-
sion is often reported as the most common comorbidity
in hospitalised COVID-19 patients, its hazard ratio for
COVID-19-related death is very close to the reference val-
ue 1 (both adjusted for age and gender and fully adjusted
for all comorbidities) [4].
During the first wave of the COVID-19 pandemic in 2020,
the health system in Switzerland was not overwhelmed in
terms of hospital bed usage and intensive care capacity.
Public health (behavioural and lock down) measures or-
dered by the federal government, the restriction of elective
procedures and an increase in ICU capacity (particularly
ventilator-equipped beds) helped to prevent resource
scarcity at national level [5]. In Switzerland, a hospital sur-
veillance system for COVID-19 (CH-Sur), coordinated by
the Swiss Federal Office of Public Health and the Institute
of Global Health of the University of Geneva [6], consist-
ing of 20 voluntary participating large central and univer-
sity hospitals across the country, was put in place. From
the end of February to the end of August 2020, the CH-
Sur surveillance system provided clinical information for
3656 episodes of 3651 patients (both paediatric and adult),
which account for more than two thirds of all patients
mandatorily reported to be hospitalised for COVID-19 in
Switzerland up to that date [6]. Using data from this in-
hospital surveillance system, the aim of this study was to
explore risk factors for in-hospital mortality and admission
to an ICU due to COVID-19 in Switzerland, as an example
of a country which was able to cope well during the first
wave of the pandemic.
Materials and methods
Participants
Adults (≥18 years of age) hospitalised for at least 24 hours
in any of the hospitals participating in the CH-Sur, and
with a - diagnosis of COVID-19 confirmed by a poly-
merase chain-reaction (PCR) test were included. A more
detailed description of the data collection and descriptive
statistics is provided in Thiabaud et al. [6]. Data were
entered online in a secured REDCap database (Research
Electronic Data Capture, Vanderbilt University, US, hosted
by the University Hospital Geneva at their Clinical Trial
Unit ).
The case report form (CRF) included demographic infor-
mation (age and gender), admission data (height, body
weight, body mass index, obesity as assessed by the physi-
cian, severity score at admission [CURB-65 score], and in-
formation on the episode [e.g., type of exposure, starting
date of symptoms, symptoms and description of laboratory
results] and was agreed with the participating hospitals to
be compulsory. Additional complementary clinical infor-
mation (e.g., comorbidities, smoking, antiviral treatment,
complications and admission to ICU and type of ventila-
tion) was optional, whereas outcome or follow-up (e.g.,
death, discharge and transfer) was mandatory. The CRF
was to be completed within 48 hours of the patient’s ad-
mission, whereas the follow-up and optional part of the
questionnaire was completed at patient’s discharge, trans-
fer or death. Discharged patients included both recovered
and those discharged (presumably not infectious anymore)
to a nursing home. Transfer was defined as transfer to a
hospital outside our surveillance network. Patients trans-
ferred to a hospital inside the surveillance network retained
their unique identifier in order to account for some patients
entering and leaving the same or different hospitals several
times. The data collection allowed for multiple re-admis-
sions per patient. If re-admission to a CH-Sur hospital oc-
curred within 30 days from the date of discharge of the first
admission, it was considered as the same episode (thus re-
taining the original entry date as the admission date). In
the cases in which the re-admission occurred more than 30
days after the date of discharge, it was considered a new
episode with a new hospitalisation admission date. In the
case of patients with several re-admissions, only the last or
final outcome was considered for the present analysis.
Data entry started on 1 March 2020, was prospective and
is still ongoing. Data were also entered in CH-Sur database
retrospectively (from the hospital’s database), when a sud-
den surge of cases caused delays in data entry or if a hos-
pital joined after the project start. The data for the pre-
sent study included patients hospitalised up to 1 September
2020, and was extracted on 15 January 2021, just after one
large hospital transferred the complementary part of the
data by an electronic data transfer from the hospital’s data-
base to the CH-Sur database.
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Ethics approval
This study was submitted and approved by the Geneva
Ethics Committee (CCER) and by all hospitals’ local
Ethics Committees through the Swiss ethics BASEC sub-
mission system, under reference 2020-00827.
Statistical analysis
The following covariates at the time of hospitalisation
were chosen a priori: age (as a continuous numerical vari-
able), gender, hypertension, diabetes, dementia, chronic
respiratory disease including asthma, cardiovascular dis-
ease, renal disease, oncological pathologies, liver disease,
human immunodeficiency virus (HIV) infection, tubercu-
losis, immunosuppression (other than HIV), smoking and
obesity (yes/no, as diagnosed by the treating physician).
We first explored the effect of different covariates on the
two primary outcomes (death and admission to ICU) using
(1) univariable models, (2) multivariable models using on-
ly the complete cases for each variable and (3) multivari-
able models using multiple imputation. Imputation was
carried out using R package mice (multiple imputation
with chained equations). For each analysis, the regression
models were run on 20 imputed datasets and estimates then
combined using Rubin’s rules [7].
Age was fitted as a continuous variable using restricted cu-
bic splines [8, 9]. Regression coefficient estimates for giv-
en/specific ages were obtained after having specified a ref-
erence age. The reference age was set to the first quartile
of total patients, 55 years.
Duration of hospital stay in days was measured from the
day of the first positive test for COVID-19 infection until
death, discharge or transfer to another hospital not partic-
ipating in the CH-Sur, whichever occurred first. Patients
admitted to the hospital but for whom the hospitalisation
outcome was unknown were considered as still in care, and
censored at database closure. First, the cumulative inci-
dence of mortality, overall and by age, gender and comor-
bidities were visualised and then hazard ratios computed
[10–12] using the R packages cmprsk and survival. Given
the elevated median age of the patients hospitalised and the
existence of comorbidities, we compared two types of pro-
portional hazard models, Cox, and Fine and Gray models,
with and without taking into account competing risks, re-
spectively. In the Cox model, the outcome of interest was
death, and all other outcomes (discharge, transfer, still in
care) were considered equivalent to censoring. In the Fine
and Gray model, the outcome of interest was also death,
but discharge and transfer were considered as competing
events, and still in care was considered as censoring [13].
In the Cox approach, out of a total 543 adult deaths, three
patients who were tested on the day of death were ren-
dered a time to event equal to zero and had to be excluded,
thus leaving 540 deaths out of 3587 patients that could be
used for the survival analysis. Because of the higher num-
ber of different variables that are necessary to compute the
outcome variable (with four categories instead of just two:
death, discharged, transferred and still in care) in the Fine
and Gray approach, a higher number of unknown or non-
plausible conditions appeared, which had to be excluded
(total n = 40): (1) three deceased patients tested on the day
of death (time to event zero, as in the Cox model), (2) 16
additional survivors also with zero time to event (in this
case, discharge or transfer), (3) one patient reported dis-
charged one day before confirmed diagnosis, and finally,
(4) 20 patients with unknown time to event. Thus, for the
Fine and Gray approach, 540 deaths out of 3550 patients
could be used. Preliminary analysis showed that both types
of models rendered similar results so we opted for the Fine
and Gray model for the final analysis, since this model is
more adequate for elderly and fragile patients.
Risk factors for ICU admission were analysed by using lo-
gistic regression models. Patients without any ICU admis-
sion recorded were assumed to not having been to ICU.
Continuous variables such as age were fitted using splines
(see above). In a preliminary analysis, the effect of cluster-
ing within a hospital was evaluated using random intercept
models fitted additionally. For each model, the intra-class
correlation coefficient (ICC) was calculated. Owing to a
low number of patients per hospital, only 10 hospitals with
at least 8 patients each could be included in these analyses.
Since the ICCs were always smaller than 10%, we opted to
exclude the random effects.
We used R version 4.0.3 (R Core Team, Vienna, Austria).
Results
For the present study, only adult patients (n = 3590, 543
deaths and 710 patients admitted to an ICU) entered in
the database as per 1 September 2020, 8:58h (last date of
extraction 15 January 2021) were included in the analy-
sis. The data thus originate from 17 of the 20 participating
hospitals, as 3 purely paediatric hospitals were excluded.
Of the 3590 patients, 543 (15.1%) died, 220 (6.1%) were
transferred to another hospital, 2793 (77.8%) were dis-
charged from the hospital and 34 (0.95%) can be assumed
to still be hospitalised as of 1 September 2020.
The median age of admitted patients was 68 years (in-
terquartile range [IQR] 55–80) years. A total of 2138
(59.5%) were men; 859/3590 (23.9%) patients had no co-
morbidity and 37/859 (4.3%) of these patients died. Table
1 (and supplementary table S1 in the appendix) shows the
outcome for patients stratified by sex, age category, num-
ber of comorbidities and CURB-65 score at admission. On
admission, 1106 (30.8%) patients presented a CURB-65
score of zero, yet 142/1106 (12.8%) of these patients re-
quired later admission to ICU of whom 9 (0.8%) died.
Thirty-eight percent of patients with a CURB-65 of three
or more on admission presented a fatal outcome.
Median duration hospitalisation from confirmatory PCR
test was 9 days (IQR 5–18). Overall, 710 (19.42%) had
been admitted to an ICU: median length of stay 12 days
(IQR 4–21, range 0–107). Of the 710 patients treated in
intensive care, 95 (13.4%) did not receive ventilation, 53
(7.5%) received only noninvasive ventilation, 519 (73.1%)
were ventilated invasively and 42 (5.9%) received invasive
ventilation and extra-corporeal membrane oxygenation
(ECMO). Of the patients who died, 170 (31.3%) had been
admitted to the ICU; 7 (1.3%) received only noninvasive
ventilation, 132 (24.3%) were ventilated invasively and 18
(3.3%) received ECMO.
The most common comorbidity was hypertension (~65%
of patients older than 65 years of age, for both genders),
followed by cardiovascular disease (51% vs 38% in men
and women, respectively, older than 65 years of age) (table
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2). Roughly a third of patients older than 65 presented a
history of diabetes, and a quarter of older patients had re-
nal disease, chronic respiratory disease or were obese. Less
common comorbidities were cancer, followed by immuno-
suppression and liver disease; tuberculosis and HIV infec-
tion were very rare. With the exception of dementia and
obesity, comorbidities occurred more often in men. Smok-
ing was twice as common in men (14%) than in women
(7%). However, a quarter of patients’ files did not have in-
formation on obesity and almost 43% were also missing
data for smoking, so these results might contain bias.
A combination of hypertension, cardiovascular medica-
tion, renal disease and diabetes was observed in many pa-
tients (fig. 1). About 67% of patients older than 65 years
had one or more of these conditions.
Most comorbidities were more frequent with increasing
age, except chronic respiratory disease, diabetes and obe-
sity (not presented because of a high proportion of missing
values), which appeared to be less frequent for patients
older than 80 years of age (fig. 2).
Cumulative incidence of survival
Overall the cumulative probability of death was around
12% after 1 month and reached 15% (slightly higher in
men) after 3 months (fig 3, panels A and B). However,
when considering different age and gender groups, we
found that the cumulative probability of death in men 80+
was above 40% and that of women almost 25% (fig. 3,
panels C and D). Most deaths in the elderly aged 80+ oc-
curred within 15 days after confirmed COVID-19 infection
and many more 80+ men than women died. When only el-
derly patients with the most common comorbidities were
plotted a similar pattern was observed (see supplementary
figure S1 in the appendix).
Risk factors for in-hospital mortality according to the
Fine and Gray survival regression model
All versions of the Fine and Gray survival regression mod-
el results (univariable, multivariable complete cases and
multivariable with multiple imputations) were congruent
with each other (table 3). Consistently, older age, male
gender, renal disease, oncological pathologies, chronic res-
piratory disease, cardiovascular disease and dementia were
associated with a higher risk of in-hospital death. The high-
est adjusted hazard ratios were obtained for older age (age
was fitted as a numerical continuous variable, see Methods
section), whereas the rest of the comorbidities presented
adjusted hazard ratios smaller than 2. The characteristics of
Table 1: Demographic information and number of comorbidities per patient for 3590 adult patients hospitalised for COVID-19 in Switzerland.
Characteristics Categories n Not admitted to ICU,
alive
Admitted to ICU, alive Not admitted to ICU,
dead
Admitted to ICU, dead
Sex Male 2138 1372 (64.2%) 404 (18.9%) 244 (11.4%) 118 (5.5%)
Female 1452 1135 (78.2%) 136 (9.4%) 129 (8.9%) 52 (3.6%)
Age (years) 18–50 591 501 (84.8%) 85 (14.4%) 2 (0.3%) 3 (0.5%)
50−64 980 713 (72.8%) 221 (22.6%) 10 (1%) 36 (3.7%)
65−80 1119 724 (64.7%) 210 (18.8%) 94 (8.4%) 91 (8.1%)
80+ 900 569 (63.2%) 24 (2.7%) 267 (29.7%) 40 (4.4%)
Number of comorbidities 0 859 695 (80.9%) 127 (14.8%) 20 (2.3%) 17 (2%)
1 846 630 (74.5%) 126 (14.9%) 50 (5.9%) 40 (4.7%)
2 779 542 (69.6%) 116 (14.9%) 77 (9.9%) 44 (5.6%)
3 542 336 (62%) 89 (16.4%) 86 (15.9%) 31 (5.7%)
>3 564 304 (53.9%) 82 (14.5%) 140 (24.8%) 38 (6.7%)
CURB−65 score 0 1106 954 (86.3%) 133 (12%) 10 (0.9%) 9 (0.8%)
1 1236 902 (73%) 191 (15.5%) 81 (6.6%) 62 (5%)
2 819 477 (58.2%) 128 (15.6%) 158 (19.3%) 56 (6.8%)
3 345 154 (44.6%) 68 (19.7%) 95 (27.5%) 28 (8.1%)
>3 84 20 (23.8%) 20 (23.8%) 29 (34.5%) 15 (17.9%)
Data are numbers (percentages) and add up to 100% along each row. Data included up to 1 September 2020 (date of extraction 15 January 2021). Missing values have been
excluded.
Table 2: Frequency of comorbidities by age category and gender for 3590 adult patients hospitalised for COVID-19 in Switzerland.
Men <65 Women <65 Men >65 Women >65
Total patients per age group 970 601 1168 851
Diabetes 149 (15.4%) 79 (13.1%) 359 (30.7%) 206 (24.2%)
Cardiovascular disease 126 (13%) 41 (6.8%) 599 (51.3%) 328 (38.5%)
Hypertension 280 (28.9%) 141 (23.5%) 773 (66.2%) 556 (65.3%)
Renal disease 58 (6%) 25 (4.2%) 310 (26.5%) 193 (22.7%)
Liver disease 44 (4.5%) 21 (3.5%) 56 (4.8%) 37 (4.3%)
Oncological pathology 55 (5.7%) 36 (6%) 196 (16.8%) 95 (11.2%)
HIV 11 (1.1%) 7 (1.2%) 5 (0.4%) 2 (0.2%)
Tuberculosis 10 (1%) 4 (0.7%) 5 (0.4%) 2 (0.2%)
Chronic respiratory disease incl. asthma 152 (15.7%) 103 (17.1%) 294 (25.2%) 178 (20.9%)
Immunosuppression other than HIV 69 (7.1%) 45 (7.5%) 86 (7.4%) 68 (8%)
Dementia 8 (0.8%) 7 (1.2%) 133 (11.4%) 137 (16.1%)
HIV = human immunodeficiency virus Data are numbers (percentages) unless stated otherwise. Data included up to 1 September 2020 (date of extraction 15 January 2021).
Missing values have been excluded. Obesity and smoking are not presented in this table, because of a high proportion of missing values of 24% and 28%, respectively.
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the patients used for these analyses are presented in table
S2 (in the appendix). The proportion of missing values by
the final date of data extraction on 15 January 2021 was
very low for all variables except for immunosuppression
(but in all previous data extractions in 2020 was around
10–15% and this is why we performed multiple imputa-
tion). Due to sparse data, HIV and tuberculosis could not
be considered as risk factors in the final regression models.
Factors associated with admission to ICU
Male patients, patients with hypertension, or aged between
55 and 79 years were admitted more often to the ICU (table
4). Patients aged 80+, as well as patients with dementia or
with liver disease were admitted less often to an ICU. The
characteristics of the patients used for these analyses are
presented in table S3 (appendix).
Discussion
Main findings
Our study found that the effect of increasing age was by
far the strongest factor (fully adjusted hazard ratios larger
than 2 for ages older than 55 years) for in-hospital mortal-
ity after having adjusted for gender and the most common
comorbidities. In addition, male gender remained an im-
portant risk factor in the multivariable models. Of all co-
morbidities that we were able to explore with the available
data, mainly renal disease and oncological pathologies,
cardiovascular disease, chronic respiratory disease and de-
mentia were associated with a higher risk of in-hospital
mortality, after adjustment for age and gender. The higher
mortality among patients with renal disease may reflect the
higher burden of comorbidity known for these patients.
Male patients, those with hypertension and aged between
55 and 79 years were more likely to be admitted to an ICU,
after adjustment for all comorbidities. The pattern was dif-
ferent from that of death, as patients with higher chances
of survival (e.g., patients younger than 80 years) were ad-
mitted to an ICU more often than aged patients with mul-
tiple comorbidities (especially those with liver disease and
dementia). Given that triage was not necessary in Switzer-
land during the first wave [5], these results suggest that
these patients might have had advanced care planning, or
might have more often decided to refrain from intensive
care treatment to prolong life.
Strengths and weaknesses
Our study has a very high coverage/surveillance rate as
CH-Sur was able to collect and analyse data of about 80%
of all COVID-19 hospitalisations reported mandatorily in
Switzerland up to 1 September 2020. All regions are repre-
sented, and each contributing hospital reported all patients.
On the other hand, due to the circumstances of data collec-
tion during the pandemic, this and other similar COVID-19
hospital datasets are susceptible to collider bias [14], see
also [15] for an in-depth analysis.
In spite of its high coverage, the size of the dataset in-
evitably sets limitations. The low frequency of comorbidi-
ties, such as HIV and tuberculosis, did not allow their in-
clusion in the regression models, but these have not been
Figure 1: Scaled Euler diagrams by age and gender showing the overlap of the five most common comorbidities for 3590 adult patients hospi-
talised for COVID-19 in Switzerland. Data included up to 1 September 2020 (date of extraction 15 January 2021). Missing values have been
excluded.
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reported as risk factors in other studies. Asthma could only
be analysed as included in chronic respiratory disease. Eth-
nicity could not be evaluated because it was absent in the
data catalogue. Other tentative risk factors such obesity
and smoking presented at the time of analysis a non-neg-
ligible fraction of missing data, which did not allow fur-
ther analysis, but are currently subject of an analysis that
includes the second winter wave (October 2020 to pre-
sent). Obesity has already been recognised as a risk factor
for symptomatic COVID-19, especially for hospital admis-
sion and ICU admission, but the risk for mortality is lower
(overall odds ratio for severe COVID-19 disease of 2) [16].
Even though comorbidities in CH-Sur are medical diag-
nosis-based on precise criteria, no distinction was made
between severe and moderate forms of comorbidities. For
this reason it is possible that our hazard ratios might be on
the lower range of the estimate. A large population study
from the UK has shown that the risk of severe COVID dis-
ease and death is higher with more severe stages of some
comorbidities [4].
Comparison with other studies
In contrast to other studies that included a mixture of co-
morbidities and laboratory markers in their models [2] and
references therein, we chose to include only comorbidi-
ties (i.e., diagnoses from medical records) as risk factors.
Studies that include laboratory markers often aim to devel-
op scores for patient management or to predict in-hospital
mortality, which is a focus different from the one in our
study. One advantage of including fewer and less correlat-
ed factors in the regression models is the reduction of mul-
ticollinearity, which is known to increase the uncertainty of
the estimates.
Our findings for mortality are consistent with a review
of 22 published survival models [2], which showed that
age is the strongest predictor for in-hospital mortality. We
also found similar risk factors as the extensive studies
carried out in the UK on in-hospital mortality [3] and
COVID-19-related death (which included suspected cases)
[4]. Of note, our estimate of hazard ratios for ages older
than 80 years is about half the hazard ratio mortality for the
same age class reported in the UK for in-hospital mortality
[3], whereas the rest of our estimates were similar in mag-
nitude.
As for the mechanisms upon which age is responsible for
severe COVID-19 disease, they are currently the subject
of intensive research. Some studies [17, 18] have proposed
a certain angiotensin converting-enzyme (ACE) profile in
the bloodstream in the elderly; others are investigating im-
muno-senescence (weakened immune system) [19, 20] as
the cause for higher susceptibility or propensity to more se-
vere COVID disease at higher ages.
This same abovementioned review [2] reported oxygen
saturation upon admission as the best predictive factor for
deterioration while in the hospital (clinical deterioration
here measured as a composite outcome of both ICU ad-
mission and death, or progression to severe COVID-19).
Figure 2: Proportions of patients with and without comorbidities in four age classes for 3590 adult patients hospitalised for COVID-19 in
Switzerland. Data included up to 1 September 2020 (date of extraction 15 January 2021). Missing values have been excluded. Obesity and
smoking are not presented in this figure, owing to a high proportion of missing values, 25% and 43%, respectively.
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Given that this marker was not available in our data cata-
logue, we cannot confirm this result. Our results for ICU
admission partly concur with those of Galloway [21] and
other references in [2] (e.g., Huang et al. [22]) which re-
ported hypertension and male gender as risk factors for the
combined outcome ICU admission and death. In contrast
to these last three mentioned studies, we considered both
outcomes, death and ICU admission, separately.
With respect to implications for policy, and the definition
of population at risk at a national level [23], evaluating risk
factors for in-hospital mortality and ICU admission is of
utmost importance in order to better define the population
at risk for adverse outcomes who need to be protected by
public health measures such as the current and future vac-
cination programmes. The risk factors can be very different
for ICU admission and in-hospital mortality, as we have
shown here by considering these outcomes separately. Hy-
pertension seemed associated with ICU admission, where-
as renal disease was a stronger risk factor for in-hospital
mortality. Older age and male gender were, however, com-
mon factors for both outcomes.
During the first wave of the epidemic in Switzerland, ac-
cess to care was always ensured even in the two most af-
fected regions. In-hospital mortality was much lower in
Switzerland than in the UK (15% [6] vs 25% [3] respec-
tively). A more controlled epidemic combined with a high
standard and easy access to medical care (better manage-
ment of patients with multiple morbidities) might have re-
sulted in this higher survival in Switzerland. A different
picture might emerge for the second autumn/winter wave
of the epidemic in Switzerland, so future studies should ad-
dress the comparison between the two waves.
Conclusion
We conclude that increasing age is the most an important
risk factor for in-hospital mortality in hospitalised
COVID-19 patients in Switzerland, along with male gen-
der and followed by the presence of comorbidities such
as renal diseases, chronic respiratory and cardiovascular
disease, oncological malignancies and dementia. In con-
trast, male gender, hypertension and age between 55 and
79 years are risk factors for ICU admission. Mortality and
ICU admission outcomes need to be considered separately
when investigating risk factors for pandemic control mea-
sures (such us vaccination priority groups) and for hospital
resource planning.
Accessing the data
The anonymised data can be accessed through a multi-
stage process described in Thiabaud et al. [6] (see appen-
Figure 3: Cumulative distribution functions by gender for 3550 adult patients hospitalised for COVID-19 in Switzerland. Left panels A,C: male
patients, right panels B,D: female patients. Panels A,B: all three outcomes – death, discharge and transfer – Panels C,D: outcome death in
three age classes. Data included up to 1 September 2020 (date of extraction 15 January 2021). Time to event is defined as the time elapsed
from confirmed COVID-19 infection to the event of interest (death, discharge, transfer).
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Age (years) p <0.001 p <0.001 p <0.001
35 0.06 (0.03−0.13) 0.11 (0.05−0.25) 0.1 (0.08−0.12)
55 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
65 2.94 (2.31−3.73) 2.4 (1.89−3.06) 2.46 (2.33−2.59)
80 7.61 (5.61−10.31) 5.75 (4.18−7.9) 5.6 (5.23−6)
Gender p <0.001 p <0.001 p <0.001
Female 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Male 1.37 (1.14−1.63) 1.42 (1.17−1.74) 1.47 (1.41−1.53)
Renal disease p <0.001 p <0.001 p <0.001
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 3.43 (2.88−4.09) 1.65 (1.34−2.03) 1.56 (1.5−1.63)
Oncological pathology p <0.001 p <0.001 p <0.001
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 2.55 (2.08−3.13) 1.56 (1.24−1.95) 1.55 (1.48−1.63)
Chronic respiratory disease (including
asthma)
p <0.001 p = 0.021 p <0.001
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 1.59 (1.32−1.92) 1.27 (1.04−1.56) 1.22 (1.17−1.27)
Cardiovascular disease p <0.001 p = 0.015 p <0.001
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 3.49 (2.94−4.14) 1.3 (1.05−1.61) 1.44 (1.38−1.51)
Liver disease p = 0.14 p = 0.77 p = 0.016
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 1.32 (0.92−1.91) 1.06 (0.71−1.6) 1.11 (1.02−1.2)
Dementia p <0.001 p = 0.26 p <0.001
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 2.93 (2.35−3.65) 1.17 (0.89−1.52) 1.22 (1.16−1.29)
Diabetes p <0.001 p = 0.28 p = 0.001
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 1.58 (1.32−1.9) 1.12 (0.91−1.38) 1.07 (1.03−1.12)
Hypertension p <0.001 p = 0.69 p = 0.26
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 2.26 (1.89−2.7) 0.96 (0.78−1.18) 0.98 (0.93−1.02)
Immunosuppression (other than HIV) p = 0.0037 p = 0.71 p = 0.0098
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 1.51 (1.14−1.99) 1.06 (0.79−1.41) 1.08 (1.02−1.15)
HIV = human immunodeficiency virus The regression models used are the proportional hazards Fine and Gray survival models, calculated univariable and multivariable, both as
complete cases and using multiple imputation with chained equations (mice). Age was fitted as a continuous variable using restricted cubic splines [9, 10]. Regression coefficient
estimates for given/specific ages were obtained after having specified a reference age. The reference age was set to the first quartile, 55 years.
dix): “Applicants must fill a concept-sheet and send it to
the team in charge of the study. An Executive Committee
of experts and representatives of hospital participants will
review the concept. Depending on the goal of the analysis,
additional ethics clearance might be needed. Data will be
restricted to the request and shared through a secure plat-
form.”
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Table 4: Odds ratios (95%CI) for ICU admission in hospitalised COVID-19 patients (n = 3590) in Swiss hospitals.







Age (years) p <0.001 p <0.001 p <0.001
35 0.26 (0.2−0.34) 0.27 (0.2−0.37) 0.31 (0.23−0.4)
55 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
65 1.22 (1.12−1.32) 1.16 (1.06−1.27) 1.15 (1.06−1.26)
80 0.42 (0.35−0.51) 0.4 (0.31−0.51) 0.41 (0.33−0.51)
Gender p <0.001 p <0.001 p <0.001
Female 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Male 2.17 (1.81−2.61) 1.85 (1.51−2.27) 1.91 (1.58−2.31)
Renal disease p = 0.022 p = 0.95 P = 0.6
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 0.76 (0.6−0.96) 1.01 (0.75−1.35) 0.93 (0.71−1.22)
Oncological pathology p = 0.01 p = 0.13 p = 0.062
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 0.68 (0.51−0.91) 0.77 (0.55−1.08) 0.74 (0.54−1.02)
Chronic respiratory disease (including
asthma)
p = 0.27 p = 0.83 p = 0.59
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 1.12 (0.92−1.37) 1.03 (0.82−1.29) 1.06 (0.86−1.31)
Cardiovascular disease p = 0.69 p = 0.14 p = 0.28
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 0.96 (0.81−1.15) 1.19 (0.94−1.51) 1.12 (0.91−1.4)
Liver disease p = 0.088 p = 0.023 p = 0.0085
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 0.68 (0.43−1.06) 0.56 (0.34−0.92) 0.53 (0.33−0.85)
Dementia p <0.001 p = 0.019 p = 0.057
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 0.32 (0.2−0.49) 0.48 (0.26−0.89) 0.63 (0.39−1.01)
Diabetes p <0.001 p = 0.1 p = 0.066
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 1.41 (1.17−1.7) 1.22 (0.96−1.53) 1.22 (0.99−1.51)
Hypertension p = 0.021 p = 0.036 p = 0.0089
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 1.21 (1.03−1.43) 1.26 (1.01−1.56) 1.3 (1.07−1.59)
Immunosuppresion (other than HIV) p = 0.63 p = 0.74 p = 0.84
No 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Yes 0.92 (0.67−1.28) 0.94 (0.67−1.33) 0.97 (0.68−1.36)
HIV = human immunodeficiency virus; ICU = intensive care unit Logistic regression models calculated univariable and multivariable, both as complete cases and using multiple
imputation with chained equations (mice). Age was fitted as a continuous variable using restricted cubic splines [9, 10]. Regression coefficient estimates for given/specific ages
were obtained after having specified a reference age. The reference age was set to the first quartile, 55 years.
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Appendix Supplementary material
Table S1: Characteristics of all patients, ICU admission and outcome, by age class and gender.





Normal (710, 45.2%) Alive (703, 99.0%)
Dead (7, 1.0%)




Normal (516, 85.9%) Alive (511, 99.0%)
Dead (5, 1.0%)






Normal (478, 68.7%) Alive (415, 86.8%)
Dead (63, 13.2%)




Normal (340, 80.4%) Alive (309, 90.9%)
Dead (31, 9.1%)






Normal (428, 90.7%) Alive (254, 59.3%)
Dead (174, 40.7%)




Normal (408, 95.3%) Alive (315, 77.2%)
Dead (93, 22.8%)
ICU (20, 4.7%) Alive (6, 30.0%)
Dead (14, 70.0%)
ICU = intensive care unit Data includes patients hospitalized up to 1 September 2020 (data extracted from the CH-Sur database on 15 January 2021).































































































HIV = human immunodeficiency virus Age is given as median and quartiles. Data includes patients hospitalised up to 1 September 2020 (data extracted from the CH-Sur database
on 15 January 2021).
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HIV = human immunodeficiency virus; ICU = intensive care unit Age is given as median and quartiles. Data includes patients hospitalized up to 1 September 2020 (data extracted
from the CH-Sur database on 15 January 2021).
Figure S1: Cumulative incidence of death for patients aged 80+ (panel A male, panel B female) and according to the following comorbidities:
renal disease, oncological pathologies, cardiovascular disease and chronic respiratory disease. Data includes patients hospitalised up to 1
September 2020 (data extracted from the CH-Sur database on 15 January 2021). Time to event is defined as the time elapsed from confirmed
COVID-19 infection to death.
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